No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 13 of the 40 quarters in the window, leaving 27 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:59:05.743Z. Latest historical point 2025-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Soligenix, Inc. (SNGX) stock was $0.36 as of Oct 6, 2026, 3:51 PM EDT, up 0.22% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -73.8% · 3-year avg -66.0%/yr · 5-year avg -72.7%/yr
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions.
Biotechnology · Princeton, NJ
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.12
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.12
vs Estimate
$-0.15
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SNGX | $5.33M | $0.36 | +0.22% | -73.75% | -72.72% | -57.62% | N/A |
| 2LEXX | $5.33M | $3.23 | +16.43% | -78.83% | -50.86% | N/A | vs SNGX |
| 3GELS | $5.32M | $0.58 | +6.67% | -57.02% | N/A | N/A | vs SNGX |
| 4INBS | $5.24M | $1.58 | -5.39% | -85.59% | -80.26% | N/A | vs SNGX |
| 5ALZN | $5.23M | $1.38 | -2.48% | -44.11% | -79.14% | N/A | vs SNGX |
| 6LNAI | $5.21M | $1.15 | +0.77% | -88.84% | N/A | N/A | vs SNGX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$1.38
+282.2% upside
Low
$1.25
Current
$0.36
High
$1.50
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Quarter ending Dec 2026 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Quarter ending Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Quarter ending Jun 2027 | $-0.06 | $-0.06 | $-0.06 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| FY 2027 | $-0.25 | $-0.25 | $-0.25 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $800000.00 | $800000.00 | $800000.00 | 1 |
| FY 2027 | $1.00M | $1.00M | $1.00M | 1 |
